Am I seeing this n a good light? There`s no reverse split. They plan to uplist because of the independent auditor. If they go to the NYSE AMEX division, their price has to be at $3.00. If they pick NASDQ, price is $4.00. SO we`ll get PR`s that will get the price up to $3.00 or $4.00. Does this sound right?
Brez~ found this info about toxicity studies on the FDA web site. Can you interpret this for us? Thanx a million~ Repeated-dose toxicity studies in two species (one nonrodent) for a minimum duration of 2 weeks (Table 1) would generally support any clinical development trial up to 2 weeks in duration. Clinical trials of longer duration should be supported by repeated-dose toxicity studies of at least equivalent duration.
Market Data 
Markets 
AI
